ArticleJournal of anesthesia2026
In vitro effects of remimazolam on human platelet function and a possible flumazenil-sensitive and non-sensitive pathway.
Article in Journal of anesthesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRemimazolam is a novel benzodiazepine intravenous sedative that is reversible by flumazenil. The related drug midazolam inhibits platelet aggregation through multiple pathways, but the effect of remimazolam on platelet function remains unclear. The aim of this study is to investigate the effect of remimazolam (Anerem
methodsVenous blood from healthy volunteers was incubated with remimazolam (3-300 μg/mL) in platelet-rich plasma and whole blood. Dextran, an excipient in Anerem
resultsAt 3 μg/mL, corresponding to clinical plasma levels, remimazolam showed no effect on platelet function. However, at 300 μg/mL, both ADP-induced platelet aggregation and P-selectin expression were significantly inhibited. The inhibition of aggregation was antagonized by flumazenil, but the reduced P-selectin expression was not reversed. Neither dextran nor flumazenil alone showed significant effects, and platelet count and MPV remained unchanged.
conclusionRemimazolam (Anerem
Indexed as
Identifiers
41817700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.